Company Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.
The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies.
It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder.
The company has license and collaboration agreements with Healx, AstraZeneca AB, H.
Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc.
The company was incorporated in 2014 and is headquartered in New York, New York.
| Country | United States |
| IPO Date | May 5, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. |
Contact Details
Address: 1460 Broadway New York, New York United States | |
| Website | https://www.ovidrx.com |
Stock Details
| Ticker Symbol | OVID |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001636651 |
| CUSIP Number | 690469101 |
| ISIN Number | US6904691010 |
| Employer ID | 46-5270895 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Chief Executive Officer & Chairman |
| Meg Alexander | President & Chief Operating Officer |
| Dr. Dirk Haasner | Senior Vice President of Global Manufacturing & CMC QA |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development |
| Dr. Toshiya Nishi D.V.M. | Head of Epilepsy Research |
| Garret Bonney | Investor Relations Officer |
| Jeffrey A. Rona | Chief Business and Financial Officer |
| Tom Parry | Vice President of Research and Early Development |
| Zhong Zhong Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 4 | Filing |
| Sep 11, 2024 | 3 | Filing |
| Sep 11, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 13, 2024 | 8-K | Current Report |
| Aug 02, 2024 | 8-K | Current Report |